person · Reporting owner

Casdin Eli

Disclosed activity across 14 companies

Tapewire entity: 36006
SEC CIK: 0001534264

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Absci CorpABSI · Entity 4685	Director	June 08, 2022	June 10, 2022
Century Therapeutics, Inc.IPSC · Entity 5739	Director	June 09, 2022	June 10, 2022
EXACT SCIENCES CORPEXAS · Entity 56619	Director	July 23, 2020	July 24, 2020
GeneDx Holdings Corp.WGS · Entity 1634	Director · 10% owner	June 18, 2026	June 23, 2026
STANDARD BIOTOOLS INC.LAB · Entity 6116	Director · 10% owner	June 18, 2026	June 23, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Absci Corp

Report date June 08, 2022 · Filed June 10, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.39 · Expires 2032-06-07	Direct	28,700	Reported balance After 2022-06-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-08 · Grant · Acquired 28,700 · Balance 28,700 F1: The shares subject to this option vest and become exercisable in full on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option vest and become exercisable in full on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such date.

Century Therapeutics, Inc.

Report date June 09, 2022 · Filed June 10, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.56 · Expires 2032-06-09	Direct	19,872	Reported balance After 2022-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-09 · Grant · Acquired 19,872 · Balance 19,872 F1: The option vests on the earlier of (a) June 9, 2023, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests on the earlier of (a) June 9, 2023, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.

EXACT SCIENCES CORP

Report date July 23, 2020 · Filed July 24, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,820	Reported balance After 2020-07-23 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2020-07-23 · Grant · Acquired 2,558 · Balance 8,820 F1: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy.
Common StockSEC Table I · non-derivative	IndirectBy child	225	Reported balance Holding disclosure · report date 2020-07-23 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 225
Common StockSEC Table I · non-derivative	IndirectBy child	225	Reported balance Holding disclosure · report date 2020-07-23 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 225

Filing footnotes · ownership attribution and instrument terms

F1: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy.

GeneDx Holdings Corp.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	24,093	Reported balance After 2026-06-18 transaction · row 1 1 source row Row 1 · 2026-06-18 · Exercise / conversion · Acquired 3,576 · Balance 24,093 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	4,248	Reported balance After 2026-06-18 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-06-18 · Grant · Acquired 4,248 · Balance 4,248 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F5: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-18 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-06-18 · Exercise / conversion · Disposed 3,576 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F6: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
Class A Common StockSEC Table I · non-derivative	IndirectBy Casdin Partners Master Fund, LP	3,707,164	Reported balance Holding disclosure · report date 2026-06-18 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 3,707,164 F2: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) the Reporting Person, who is the managing member of Casdin and the GP.
Class A Common StockSEC Table I · non-derivative	IndirectBy Casdin Partners GP, LLC	19,247	Reported balance Holding disclosure · report date 2026-06-18 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 19,247 F3: The securities are owned directly by the GP and may be deemed to be indirectly beneficially owned by the Reporting Person, who is the managing member of the GP.
Class A Common StockSEC Table I · non-derivative	IndirectBy CMLS Holdings LLC	333,144	Reported balance Holding disclosure · report date 2026-06-18 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 333,144 F4: The securities are owned directly by CMLS Holdings LLC ("CMLS Holdings"). The Board of Managers of CMLS Holdings includes the Reporting Person, who, as a member of the Board of Managers of CMLS Holdings, shares voting and investment discretion with respect to securities held by CMLS Holdings.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F2: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) the Reporting Person, who is the managing member of Casdin and the GP.

F3: The securities are owned directly by the GP and may be deemed to be indirectly beneficially owned by the Reporting Person, who is the managing member of the GP.

F4: The securities are owned directly by CMLS Holdings LLC ("CMLS Holdings"). The Board of Managers of CMLS Holdings includes the Reporting Person, who, as a member of the Board of Managers of CMLS Holdings, shares voting and investment discretion with respect to securities held by CMLS Holdings.

F5: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.

F6: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.

STANDARD BIOTOOLS INC.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,053,169	Reported balance After 2026-06-18 transaction · row 1 1 source row Row 1 · 2026-06-18 · Grant · Acquired 99,116 · Balance 3,053,169 F1: Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.83 · Expires 2036-06-18	Direct	175,923	Reported balance After 2026-06-18 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-06-18 · Grant · Acquired 175,923 · Balance 175,923 F5: The Option becomes exercisable in twelve equal monthly installments beginning on July 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date.
Common StockSEC Table I · non-derivative	IndirectCasdin Private Growth Equity Fund II, L.P.	13,939,637	Reported balance Holding disclosure · report date 2026-06-18 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 13,939,637 F2: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
Common StockSEC Table I · non-derivative	IndirectBy Casdin Private Growth Equity Fund, L.P.	2,744,219	Reported balance Holding disclosure · report date 2026-06-18 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 2,744,219 F3: The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.
Common StockSEC Table I · non-derivative	IndirectCasdin Partners Master Fund, L.P.	72,100,000	Reported balance Holding disclosure · report date 2026-06-18 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 72,100,000 F4: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.

Filing footnotes · ownership attribution and instrument terms

F1: Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.

F2: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.

F3: The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.

F4: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.

F5: The Option becomes exercisable in twelve equal monthly installments beginning on July 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date.

Past disclosures · reporting ended (9)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

2seventy bio, Inc.

Report date May 13, 2025 · Filed May 15, 2025

Jointly reported with Casdin Capital, LLC, Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC

Section 16 reporting ended · disclosed 2025-05-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common Stock, par value $0.0001 per shareSEC Table I · non-derivative	Direct	Reported balance After 2025-05-13 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-05-13 · Other · Disposed 22,625 · Balance 0 F1: Represents securities that were tendered in connection with the Agreement and Plan of Merger (the "Merger Agreement"), dated March 10, 2025, by and among 2seventy bio, Inc. (the "Company"), Daybreak Merger Sub Inc. ("Merger Sub") and Bristol-Myers Squibb Company ("Parent"). Following completion of a cash tender offer by Merger Sub to acquire all of the issued and outstanding shares of the Company's common stock, par value $0.0001 per share (the "Company Common Stock") for $5.00 per share (the "Merger Consideration"), Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a whole owned subsidiary of Parent (the "Merger"). F2: cont'd from footnote (1): Each restricted stock unit in respect of Company Common Stock ("Company RSU Award"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Additionally, effective as of the Effective Time and as a result of the Merger, Eli Casdin ceased to be a member of the Company's board of directors. F3: The securities were owned directly by Eli Casdin.
Common Stock, par value $0.0001 per shareSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2025-05-13 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2025-05-13 · Other · Disposed 2,000,000 · Balance 0 F1: Represents securities that were tendered in connection with the Agreement and Plan of Merger (the "Merger Agreement"), dated March 10, 2025, by and among 2seventy bio, Inc. (the "Company"), Daybreak Merger Sub Inc. ("Merger Sub") and Bristol-Myers Squibb Company ("Parent"). Following completion of a cash tender offer by Merger Sub to acquire all of the issued and outstanding shares of the Company's common stock, par value $0.0001 per share (the "Company Common Stock") for $5.00 per share (the "Merger Consideration"), Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a whole owned subsidiary of Parent (the "Merger"). F2: cont'd from footnote (1): Each restricted stock unit in respect of Company Common Stock ("Company RSU Award"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Additionally, effective as of the Effective Time and as a result of the Merger, Eli Casdin ceased to be a member of the Company's board of directors. F4: The securities were owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to have been indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.93	Direct	Reported balance After 2025-05-13 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-05-13 · Disposition to issuer · Disposed 12,050 · Balance 0 F5: Each option to purchase Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company Option immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. F3: The securities were owned directly by Eli Casdin.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.54	Direct	Reported balance After 2025-05-13 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-05-13 · Disposition to issuer · Disposed 33,400 · Balance 0 F5: Each option to purchase Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company Option immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. F3: The securities were owned directly by Eli Casdin.

Filing footnotes · ownership attribution and instrument terms

F1: Represents securities that were tendered in connection with the Agreement and Plan of Merger (the "Merger Agreement"), dated March 10, 2025, by and among 2seventy bio, Inc. (the "Company"), Daybreak Merger Sub Inc. ("Merger Sub") and Bristol-Myers Squibb Company ("Parent"). Following completion of a cash tender offer by Merger Sub to acquire all of the issued and outstanding shares of the Company's common stock, par value $0.0001 per share (the "Company Common Stock") for $5.00 per share (the "Merger Consideration"), Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a whole owned subsidiary of Parent (the "Merger").

F2: cont'd from footnote (1): Each restricted stock unit in respect of Company Common Stock ("Company RSU Award"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time") was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Additionally, effective as of the Effective Time and as a result of the Merger, Eli Casdin ceased to be a member of the Company's board of directors.

F3: The securities were owned directly by Eli Casdin.

F4: The securities were owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to have been indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.

F5: Each option to purchase Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was fully vested, was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company Option immediately prior to the Effective Time, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option.

BIOLIFE SOLUTIONS INC

Report date May 19, 2026 · Filed May 21, 2026

Jointly reported with Casdin Partners Master Fund, L.P., Casdin Capital, LLC, Casdin Partners GP, LLC

Section 16 reporting ended · disclosed 2026-05-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.001 per shareSEC Table I · non-derivative	IndirectSee footnote	4,757,165	Last balance in matching sequence After 2026-05-21 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2026-05-19 · Sale · Disposed 300,000 · Balance 5,657,165 F1: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Row 2 · 2026-05-20 · Sale · Disposed 250,000 · Balance 5,407,165 F1: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Row 3 · 2026-05-21 · Sale · Disposed 650,000 · Balance 4,757,165 F1: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP.

Filing footnotes · ownership attribution and instrument terms

F1: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP.

CONSTELLATION PHARMACEUTICALS INC

Report date July 23, 2018 · Filed July 23, 2018

Jointly reported with Casdin Capital, LLC, Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC, Casdin Venture Opportunities Fund, L.P., CASDIN VENTURE OPPORTUNITIES FUND GP, LLC

Section 16 reporting ended · disclosed 2018-07-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	345,783	Reported balance After 2018-07-23 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-07-23 · Conversion · Acquired 345,783 · Balance 345,783 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2: These securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
Common StockSEC Table I · non-derivative	IndirectSee footnote	612,450	Reported balance After 2018-07-23 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2018-07-23 · Purchase · Acquired 266,667 · Balance 612,450 F2: These securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
Common StockSEC Table I · non-derivative	IndirectSee footnote	158,960	Reported balance After 2018-07-23 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2018-07-23 · Conversion · Acquired 158,960 · Balance 158,960 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F3: These securities are owned directly by Casdin Venture Opportunities Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Venture Opportunities Fund, LP, (ii) Casdin Venture Opportunities Fund GP, LLC, the general partner of Casdin Venture Opportunities Fund, LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Venture Opportunities Fund GP, LLC.
Series E Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2018-07-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-07-23 · Conversion · Disposed 1,333,333 · Balance 0 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2: These securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
Series E-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2018-07-23 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-07-23 · Conversion · Disposed 342,435 · Balance 0 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2: These securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
Series F Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2018-07-23 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-07-23 · Conversion · Disposed 1,750,000 · Balance 0 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2: These securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
Series F Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2018-07-23 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-07-23 · Conversion · Disposed 1,750,000 · Balance 0 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F3: These securities are owned directly by Casdin Venture Opportunities Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Venture Opportunities Fund, LP, (ii) Casdin Venture Opportunities Fund GP, LLC, the general partner of Casdin Venture Opportunities Fund, LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Venture Opportunities Fund GP, LLC.

Filing footnotes · ownership attribution and instrument terms

F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.

F2: These securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

F3: These securities are owned directly by Casdin Venture Opportunities Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Venture Opportunities Fund, LP, (ii) Casdin Venture Opportunities Fund GP, LLC, the general partner of Casdin Venture Opportunities Fund, LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Venture Opportunities Fund GP, LLC.

EQRx, Inc.

Report date November 09, 2023 · Filed November 14, 2023

Section 16 reporting ended · disclosed 2023-11-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2023-11-09 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2023-11-09 · Other · Disposed 8,659,372 · Balance 0 F1: The securities were held directly by CMLS Holdings III LLC ("CMLS Holdings III"). Mr. Casdin is a member of the Board of Managers of CMLS Holdings III and as a result shares voting and investment discretion with respect to the securities held by CMLS Holdings III. Mr. Casdin disclaims beneficial ownership of these shares except to the extent of his respective pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2023-11-09 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2023-11-09 · Other · Disposed 30,214,934 · Balance 0 F2: The securities were owned directly by the Casdin Partners Master Fund, L.P. (the "Master Fund") and were deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to the Master Fund, (ii) Casdin GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Mr. Casdin disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.)
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2023-11-09 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2023-11-09 · Other · Disposed 3,824,572 · Balance 0 F3: The securities were owned directly by Casdin Venture Opportunities Fund, L.P. (the "Venture Fund") and were deemed to be indirectly bencially owned by (i) Casdin Capital, the investment adviser to the Venture Fund, (ii) Casdin Venture Opportunities Fund GP, LLC (the "Venture GP"), the general partner of the Venture Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Venture GP.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2023-11-09 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2023-11-09 · Other · Disposed 5,488,164 · Balance 0 F4: The securities were owned directly by Casdin Private Growth Equity Fund, L.P. (the "Private Fund") and were deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to the Private Fund, (ii) Casdin Private Growth Equity Fund GP, LLC (the "Private GP"), the general partner of the Private Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Private GP
Warrants to purchase Class A Common Stock (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2026-12-17	IndirectSee footnote	Reported balance After 2023-11-09 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-11-09 · Other · Disposed 8,110,001 · Balance 0 F1: The securities were held directly by CMLS Holdings III LLC ("CMLS Holdings III"). Mr. Casdin is a member of the Board of Managers of CMLS Holdings III and as a result shares voting and investment discretion with respect to the securities held by CMLS Holdings III. Mr. Casdin disclaims beneficial ownership of these shares except to the extent of his respective pecuniary interest therein.
Earn-out SharesSEC Table II · derivative / convertible security · Expires 2024-12-17	IndirectSee footnote	Reported balance After 2023-11-09 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-11-09 · Other · Disposed 3,472,300 · Balance 0 F5: The Reporting Person received the right to acquire an aggregate of 4,729,839 shares of the Issuer's Common Stock (the "Earn-out Shares") (i) 3,310,887 of which were to be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $12.50; and (ii) 1,418,952 would have been released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 would have been forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire was subject to adjustment. F2: The securities were owned directly by the Casdin Partners Master Fund, L.P. (the "Master Fund") and were deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to the Master Fund, (ii) Casdin GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Mr. Casdin disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.)
Earn-out SharesSEC Table II · derivative / convertible security · Expires 2024-12-17	IndirectSee footnote	Reported balance After 2023-11-09 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-11-09 · Other · Disposed 526,674 · Balance 0 F5: The Reporting Person received the right to acquire an aggregate of 4,729,839 shares of the Issuer's Common Stock (the "Earn-out Shares") (i) 3,310,887 of which were to be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $12.50; and (ii) 1,418,952 would have been released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 would have been forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire was subject to adjustment. F3: The securities were owned directly by Casdin Venture Opportunities Fund, L.P. (the "Venture Fund") and were deemed to be indirectly bencially owned by (i) Casdin Capital, the investment adviser to the Venture Fund, (ii) Casdin Venture Opportunities Fund GP, LLC (the "Venture GP"), the general partner of the Venture Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Venture GP.
Earn-out SharesSEC Table II · derivative / convertible security · Expires 2024-12-17	IndirectSee footnote	Reported balance After 2023-11-09 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-11-09 · Other · Disposed 755,766 · Balance 0 F5: The Reporting Person received the right to acquire an aggregate of 4,729,839 shares of the Issuer's Common Stock (the "Earn-out Shares") (i) 3,310,887 of which were to be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $12.50; and (ii) 1,418,952 would have been released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 would have been forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire was subject to adjustment. F4: The securities were owned directly by Casdin Private Growth Equity Fund, L.P. (the "Private Fund") and were deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to the Private Fund, (ii) Casdin Private Growth Equity Fund GP, LLC (the "Private GP"), the general partner of the Private Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Private GP
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.95 · Expires 2032-09-30	Direct	Reported balance After 2023-11-09 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-11-09 · Other · Disposed 101,010 · Balance 0 F6: The shares underlying this option vested and became exercisable in full on September 30, 2023, the one-year anniversary of the grant date, subject to the Reporting Person's continuous service on such vesting date, and subject to full acceleration upon the consummation of a Sale Event (as defined in the Issuer's 2021 Stock Option and Incentive Plan).

Filing footnotes · ownership attribution and instrument terms

F1: The securities were held directly by CMLS Holdings III LLC ("CMLS Holdings III"). Mr. Casdin is a member of the Board of Managers of CMLS Holdings III and as a result shares voting and investment discretion with respect to the securities held by CMLS Holdings III. Mr. Casdin disclaims beneficial ownership of these shares except to the extent of his respective pecuniary interest therein.

F2: The securities were owned directly by the Casdin Partners Master Fund, L.P. (the "Master Fund") and were deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to the Master Fund, (ii) Casdin GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Mr. Casdin disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.)

F3: The securities were owned directly by Casdin Venture Opportunities Fund, L.P. (the "Venture Fund") and were deemed to be indirectly bencially owned by (i) Casdin Capital, the investment adviser to the Venture Fund, (ii) Casdin Venture Opportunities Fund GP, LLC (the "Venture GP"), the general partner of the Venture Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Venture GP.

F4: The securities were owned directly by Casdin Private Growth Equity Fund, L.P. (the "Private Fund") and were deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to the Private Fund, (ii) Casdin Private Growth Equity Fund GP, LLC (the "Private GP"), the general partner of the Private Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Private GP

F5: The Reporting Person received the right to acquire an aggregate of 4,729,839 shares of the Issuer's Common Stock (the "Earn-out Shares") (i) 3,310,887 of which were to be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $12.50; and (ii) 1,418,952 would have been released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 would have been forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire was subject to adjustment.

F6: The shares underlying this option vested and became exercisable in full on September 30, 2023, the one-year anniversary of the grant date, subject to the Reporting Person's continuous service on such vesting date, and subject to full acceleration upon the consummation of a Sale Event (as defined in the Issuer's 2021 Stock Option and Incentive Plan).

Fulcrum Therapeutics, Inc.

Report date July 22, 2019 · Filed July 22, 2019

Jointly reported with Casdin Capital, LLC, Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC

Section 16 reporting ended · disclosed 2019-07-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	604,285	Last balance in matching sequence After 2019-07-22 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 4 source rows Row 1 · 2019-07-22 · Conversion · Acquired 464,285 · Balance 464,285 F1: On July 22, 2019, the Series B Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: The securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Row 2 · 2019-07-22 · Purchase · Acquired 125,000 · Balance 589,285 F2: The securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Row 3 · 2019-07-22 · Purchase · Acquired 10,000 · Balance 599,285 F2: The securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Row 4 · 2019-07-22 · Purchase · Acquired 5,000 · Balance 604,285 F2: The securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2019-07-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-07-22 · Conversion · Disposed 3,250,000 · Balance 0 F1: On July 22, 2019, the Series B Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: The securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

Filing footnotes · ownership attribution and instrument terms

F1: On July 22, 2019, the Series B Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: The securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

Generation Bio Co.

Report date June 16, 2020 · Filed June 18, 2020

Jointly reported with Casdin Capital, LLC

Section 16 reporting ended · disclosed 2020-06-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,611,215	Last balance in matching sequence After 2020-06-16 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2020-06-16 · Conversion · Acquired 961,215 · Balance 961,215 F1: On June 16, 2020, the Series B Preferred Stock automatically converted into Common Stock on approximately a 1.5546-for-one basis (when rounded to the nearest ten-thousandth) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The securities are owned directly by clients of Casdin Capital, LLC and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC as investment adviser to such clients and (ii) Eli Casdin as managing member of Casdin Capital, LLC. Row 2 · 2020-06-16 · Purchase · Acquired 650,000 · Balance 1,611,215 F3: The securities are owned directly by clients of Casdin Capital, LLC and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC as investment adviser to such clients and (ii) Eli Casdin as managing member of Casdin Capital, LLC.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2020-06-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-06-16 · Conversion · Disposed 1,093,410 · Balance 0 F1: On June 16, 2020, the Series B Preferred Stock automatically converted into Common Stock on approximately a 1.5546-for-one basis (when rounded to the nearest ten-thousandth) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The securities are owned directly by clients of Casdin Capital, LLC and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC as investment adviser to such clients and (ii) Eli Casdin as managing member of Casdin Capital, LLC.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2020-06-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-06-16 · Conversion · Disposed 455,500 · Balance 0 F2: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The securities are owned directly by clients of Casdin Capital, LLC and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC as investment adviser to such clients and (ii) Eli Casdin as managing member of Casdin Capital, LLC.

Filing footnotes · ownership attribution and instrument terms

F1: On June 16, 2020, the Series B Preferred Stock automatically converted into Common Stock on approximately a 1.5546-for-one basis (when rounded to the nearest ten-thousandth) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F2: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F3: The securities are owned directly by clients of Casdin Capital, LLC and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC as investment adviser to such clients and (ii) Eli Casdin as managing member of Casdin Capital, LLC.

MAXCYTE, INC.

Report date October 03, 2022 · Filed October 05, 2022

Jointly reported with Casdin Partners Master Fund, L.P., Casdin Capital, LLC, Casdin Partners GP, LLC

Section 16 reporting ended · disclosed 2022-10-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.01 per shareSEC Table I · non-derivative	Direct	10,000,000	Reported balance After 2022-10-03 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2022-10-03 · Sale · Disposed 735,786 · Balance 10,000,000 F1: (1) The securities are owned directly by Casdin Partners Master Fund, LP (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

Filing footnotes · ownership attribution and instrument terms

F1: (1) The securities are owned directly by Casdin Partners Master Fund, LP (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

SomaLogic, Inc.

Report date January 05, 2024 · Filed January 10, 2024

Section 16 reporting ended · disclosed 2024-01-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-01-05 transaction · row 1 1 source row Row 1 · 2024-01-05 · Disposition to issuer · Disposed 3,430 · Balance 0 F1: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock.
Common StockSEC Table I · non-derivative	IndirectBy CMLS Holdings II LLC	Reported balance After 2024-01-05 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2024-01-05 · Disposition to issuer · Disposed 6,800,000 · Balance 0 F1: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock. F3: The shares are held of record by CMLS Holdings II LLC ("CMLS Holdings II"). The Board of Managers of CMLS Holdings II includes Mr. Casdin, who, as a member of the Board of Managers of CMLS Holdings II, shares voting and investment discretion with respect to the common stock held by CMLS Holdings II. Mr. Casdin may be deemed to have or share beneficial ownership of the securities held by CMLS Holdings II, which include such shares and the warrants referenced in Table II.
Common StockSEC Table I · non-derivative	IndirectBy Casdin Master Fund, L.P.	Reported balance After 2024-01-05 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2024-01-05 · Disposition to issuer · Disposed 10,132,005 · Balance 0 F1: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock. F4: The securities are owned directly by Casdin Partners Master Fund, LP (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
Common StockSEC Table I · non-derivative	IndirectBy Casdin Private Growth Equity Fund, L.P.	Reported balance After 2024-01-05 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2024-01-05 · Disposition to issuer · Disposed 2,472,270 · Balance 0 F1: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock. F5: The shares held by Casdin Private Growth Equity Fund, L.P. may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Private Growth Equity Fund, L.P., (ii) Casdin Private Growth Equity GP, LLC, the general partner of Casdin Private Growth Equity Fund, L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Private Growth Equity GP, LLC.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.77 · Expires 2031-02-18	Direct	Reported balance After 2024-01-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-01-05 · Disposition to issuer · Disposed 41,905 · Balance 0 F7: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F6: The option vested as to 1/4th of the total grant on February 19, 2022, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.85 · Expires 2031-10-26	Direct	Reported balance After 2024-01-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-01-05 · Disposition to issuer · Disposed 46,705 · Balance 0 F7: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F8: The option vested as to 1/4th of the total grant on October 27, 2022, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.08 · Expires 2032-02-29	Direct	Reported balance After 2024-01-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-01-05 · Disposition to issuer · Disposed 20,600 · Balance 0 F7: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F9: The option is fully vested and exercisable.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2033-03-16	Direct	Reported balance After 2024-01-05 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-01-05 · Disposition to issuer · Disposed 20,600 · Balance 0 F7: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F10: The option shall be 100% vested on March 17, 2024, subject to the continued service of the Reporting Person on such vesting date.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2024-01-05 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2024-01-05 · Disposition to issuer · Disposed 3,430 · Balance 0 F11: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F13: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F12: The RSUs shall be 100% vested on March 17, 2024, subject to the continued service of the Reporting Person on such vesting date.
Warrant to purchase common stock (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2026-09-01	IndirectBy CMLS Holdings II LLC	Reported balance After 2024-01-05 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2024-01-05 · Disposition to issuer · Disposed 4,346,669 · Balance 0 F15: Pursuant to the Merger Agreement, each warrant to purchase Company Common Stock was treated in accordance with its terms on and after the Effective Time and each warrant will convert into the right to receive, upon exercise of such warrant, the number of shares of Parent Common Stock equal to multiplying the number of shares of Company Common Stock subject to such warrant by the Exchange Ratio. F14: Each warrant is exercisable to purchase one share of Company Common Stock at a price of $11.50 per share, subject to adjustment, as described in the Issuer's Annual Report on Form 10-K, for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission on March 28, 2023. F3: The shares are held of record by CMLS Holdings II LLC ("CMLS Holdings II"). The Board of Managers of CMLS Holdings II includes Mr. Casdin, who, as a member of the Board of Managers of CMLS Holdings II, shares voting and investment discretion with respect to the common stock held by CMLS Holdings II. Mr. Casdin may be deemed to have or share beneficial ownership of the securities held by CMLS Holdings II, which include such shares and the warrants referenced in Table II.

Filing footnotes · ownership attribution and instrument terms

F1: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger").

F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock.

F3: The shares are held of record by CMLS Holdings II LLC ("CMLS Holdings II"). The Board of Managers of CMLS Holdings II includes Mr. Casdin, who, as a member of the Board of Managers of CMLS Holdings II, shares voting and investment discretion with respect to the common stock held by CMLS Holdings II. Mr. Casdin may be deemed to have or share beneficial ownership of the securities held by CMLS Holdings II, which include such shares and the warrants referenced in Table II.

F4: The securities are owned directly by Casdin Partners Master Fund, LP (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

F5: The shares held by Casdin Private Growth Equity Fund, L.P. may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Private Growth Equity Fund, L.P., (ii) Casdin Private Growth Equity GP, LLC, the general partner of Casdin Private Growth Equity Fund, L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Private Growth Equity GP, LLC.

F6: The option vested as to 1/4th of the total grant on February 19, 2022, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.

F7: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions.

F8: The option vested as to 1/4th of the total grant on October 27, 2022, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.

F9: The option is fully vested and exercisable.

F10: The option shall be 100% vested on March 17, 2024, subject to the continued service of the Reporting Person on such vesting date.

F11: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration.

F12: The RSUs shall be 100% vested on March 17, 2024, subject to the continued service of the Reporting Person on such vesting date.

F13: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time.

F14: Each warrant is exercisable to purchase one share of Company Common Stock at a price of $11.50 per share, subject to adjustment, as described in the Issuer's Annual Report on Form 10-K, for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission on March 28, 2023.

F15: Pursuant to the Merger Agreement, each warrant to purchase Company Common Stock was treated in accordance with its terms on and after the Effective Time and each warrant will convert into the right to receive, upon exercise of such warrant, the number of shares of Parent Common Stock equal to multiplying the number of shares of Company Common Stock subject to such warrant by the Exchange Ratio.

Tenaya Therapeutics, Inc.

Report date November 17, 2022 · Filed November 26, 2022

Jointly reported with Casdin Capital, LLC

Section 16 reporting ended · disclosed 2022-11-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	6,078,860	Reported balance After 2022-11-17 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2022-11-17 · Purchase · Acquired 2,492,042 · Balance 6,078,860 F1: The securities are owned directly by clients of Casdin Capital, LLC ("Casdin Capital") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to such clients and (ii) Eli Casdin, the managing member of Casdin Capital.
WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectSee footnote	1,354,111	Reported balance After 2022-11-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-11-17 · Purchase · Acquired 1,354,111 · Balance 1,354,111 F2: Each Warrant will be exercisable on or after the date of issuance until the date the Warrant is exercised in full. Each Warrant will be exercisable, in the holder's discretion, by (i) payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise or (ii) a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to a pre-set formula. F1: The securities are owned directly by clients of Casdin Capital, LLC ("Casdin Capital") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to such clients and (ii) Eli Casdin, the managing member of Casdin Capital.

Filing footnotes · ownership attribution and instrument terms

F1: The securities are owned directly by clients of Casdin Capital, LLC ("Casdin Capital") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to such clients and (ii) Eli Casdin, the managing member of Casdin Capital.

F2: Each Warrant will be exercisable on or after the date of issuance until the date the Warrant is exercised in full. Each Warrant will be exercisable, in the holder's discretion, by (i) payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise or (ii) a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to a pre-set formula.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 17, 2024 Filed May 18, 2024 00:11 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	352,072	$2.56	$902,043.67	Disclosure SEC source: 0000919574-24-003252 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 45,375,821 F4 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.5381 to $2.5798. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
May 16, 2024 Filed May 18, 2024 00:11 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	500,000	$2.54	$1,270,950.00	Disclosure SEC source: 0000919574-24-003252 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 45,023,749 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.5381 to $2.5429. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
May 15, 2024 Filed May 18, 2024 00:11 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	500,000	$2.57	$1,282,550.00	Disclosure SEC source: 0000919574-24-003252 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 44,523,749 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.5473 to $2.58. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
May 13, 2024 Filed May 15, 2024 18:16 UTC	GeneDx Holdings Corp. WGS · Entity 1634	PurchaseClass A Common Stock	50,000	$23.31	$1,165,295.00	Disclosure SEC source: 0000919574-24-003212 · ownership.xml · nonDerivative · entry 1 Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,753,509 F1 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
April 30, 2024 Filed May 2, 2024 21:05 UTC	BIOLIFE SOLUTIONS INC BLFS · Entity 4614	OtherCommon Stock, par value $.001 per share	150,000	$17.54	$2,631,000.00	Disclosure SEC source: 0000919574-24-002732 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · 10% owner Casdin Eli · CIK 0001534264 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: Represents a cross-trade, pursuant to which a client of Casdin Capital, LLC ("Casdin Capital") transferred 150,000 shares of common Stock, par value $.001 per share to Casdin Partners Master Fund, L.P. (the "Master Fund"). F3 · ownership.nature: The securities were owned directly by a client of Casdin Capital and were deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to such client; (ii) Casdin GP, the general partner of such client, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Read SEC document
April 30, 2024 Filed May 2, 2024 21:05 UTC	BIOLIFE SOLUTIONS INC BLFS · Entity 4614	OtherCommon Stock, par value $.001 per share	150,000	$17.54	$2,631,000.00	Disclosure SEC source: 0000919574-24-002732 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · 10% owner Casdin Eli · CIK 0001534264 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,707,165 F1 · kind: Represents a cross-trade, pursuant to which a client of Casdin Capital, LLC ("Casdin Capital") transferred 150,000 shares of common Stock, par value $.001 per share to Casdin Partners Master Fund, L.P. (the "Master Fund"). F2 · ownership.direct: The securities are owned directly by the Master Fund and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Read SEC document
March 26, 2024 Filed Mar 28, 2024 20:29 UTC	2seventy bio, Inc. TSVT · Entity 79756	PurchaseCommon Stock, par value $0.0001 per share	40,000	$5.10	$203,992.00	Disclosure SEC source: 0000919574-24-002241 · ownership.xml · nonDerivative · entry 1 Casdin Capital, LLC · CIK 0001534261 · Director Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director Casdin Eli · CIK 0001534264 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 2,000,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $4.9 to $5.41. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
March 25, 2024 Filed Mar 25, 2024 21:44 UTC	2seventy bio, Inc. TSVT · Entity 79756	PurchaseCommon Stock, par value $0.0001 per share	330,000	$5.07	$1,673,991.00	Disclosure SEC source: 0000919574-24-002176 · ownership.xml · nonDerivative · entry 3 Casdin Capital, LLC · CIK 0001534261 · Director Casdin Eli · CIK 0001534264 · Director Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,960,000 F4 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $4.87 to $5.55. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
March 22, 2024 Filed Mar 25, 2024 21:44 UTC	2seventy bio, Inc. TSVT · Entity 79756	PurchaseCommon Stock, par value $0.0001 per share	147,377	$5.12	$754,069.16	Disclosure SEC source: 0000919574-24-002176 · ownership.xml · nonDerivative · entry 2 Casdin Capital, LLC · CIK 0001534261 · Director Casdin Eli · CIK 0001534264 · Director Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,630,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $4.93 to $5.21. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
March 21, 2024 Filed Mar 25, 2024 21:44 UTC	2seventy bio, Inc. TSVT · Entity 79756	SaleTotal Return Swap · Derivative	63,151	$4.72	$297,782.23	Disclosure SEC source: 0000919574-24-002176 · ownership.xml · derivative · entry 5 Casdin Capital, LLC · CIK 0001534261 · Director Casdin Eli · CIK 0001534264 · Director Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 536,784 Underlying: Common Stock, par value $0.0001 per share · 63,151 shares Expires not disclosed F8 · derivative.exercise_price: The price reported in Column 7 is a weighted average price. These securities were sold in multiple transactions within the range of $4.62 to $4.84. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F8 · price: The price reported in Column 7 is a weighted average price. These securities were sold in multiple transactions within the range of $4.62 to $4.84. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F7 · derivative.exercise_date: The Master Fund has entered into certain cash-settled total return swap agreements (the "Swap Agreements"), which represent, after the transaction reported herein, economic exposure to an aggregate of 536,784.15 notional shares of the Issuer's Common Stock, par value $0.0001 per share. The Swap Agreements provide the Master Fund with economic results that are comparable to the economic results of ownership but do not provide it with the power to vote or direct the voting or dispose of or direct the disposition of the securities that are referenced by the Swap Agreements. F7 · derivative.expiration_date: The Master Fund has entered into certain cash-settled total return swap agreements (the "Swap Agreements"), which represent, after the transaction reported herein, economic exposure to an aggregate of 536,784.15 notional shares of the Issuer's Common Stock, par value $0.0001 per share. The Swap Agreements provide the Master Fund with economic results that are comparable to the economic results of ownership but do not provide it with the power to vote or direct the voting or dispose of or direct the disposition of the securities that are referenced by the Swap Agreements. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
March 21, 2024 Filed Mar 25, 2024 21:44 UTC	2seventy bio, Inc. TSVT · Entity 79756	PurchaseCommon Stock, par value $0.0001 per share	300,000	$4.90	$1,470,990.00	Disclosure SEC source: 0000919574-24-002176 · ownership.xml · nonDerivative · entry 1 Casdin Capital, LLC · CIK 0001534261 · Director Casdin Eli · CIK 0001534264 · Director Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,482,623 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $4.63 to $5. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
March 18, 2024 Filed Mar 20, 2024 21:54 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	Disposition to issuerSeries B-1 Convertible Preferred Stock · Derivative	38,334	$2.75 Strike: $2.75	$105,418.50	Disclosure SEC source: 0000919574-24-002115 · ownership.xml · derivative · entry 8 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 13,939,637 shares Expires not disclosed F7 · derivative.exercise_date: Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") was convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share. F7 · derivative.expiration_date: Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") was convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share. F2 · ownership.nature: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin. Read SEC document
March 18, 2024 Filed Mar 20, 2024 21:54 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	Disposition to issuerSeries B-1 Convertible Preferred Stock · Derivative	89,446	$2.75 Strike: $2.75	$245,976.50	Disclosure SEC source: 0000919574-24-002115 · ownership.xml · derivative · entry 7 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 32,525,821 shares Expires not disclosed F7 · derivative.exercise_date: Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") was convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share. F7 · derivative.expiration_date: Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") was convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share. F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
March 18, 2024 Filed Mar 20, 2024 21:54 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantCommon Stock	13,939,637	$2.75	$38,334,001.75	Disclosure SEC source: 0000919574-24-002115 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 13,939,637 F2 · ownership.nature: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin. Read SEC document
March 18, 2024 Filed Mar 20, 2024 21:54 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantCommon Stock	32,525,821	$2.75	$89,446,007.75	Disclosure SEC source: 0000919574-24-002115 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 44,023,749 F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
March 05, 2024 Filed Mar 7, 2024 00:20 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	1,403	$2.62	$3,668.85	Disclosure SEC source: 0000919574-24-001888 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,497,928 F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
March 05, 2024 Filed Mar 6, 2024 19:32 UTC	GeneDx Holdings Corp. WGS · Entity 1634	PurchaseClass A Common Stock	900	$8.83	$7,944.30	Disclosure SEC source: 0000919574-24-001889 · ownership.xml · nonDerivative · entry 2 Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,703,509 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $8.8236 to $8.84. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
March 04, 2024 Filed Mar 7, 2024 00:20 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	250,000	$2.57	$642,500.00	Disclosure SEC source: 0000919574-24-001888 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,496,525 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $2.5525 to $2.616. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
March 04, 2024 Filed Mar 6, 2024 19:32 UTC	GeneDx Holdings Corp. WGS · Entity 1634	PurchaseClass A Common Stock	40,000	$8.74	$349,708.00	Disclosure SEC source: 0000919574-24-001889 · ownership.xml · nonDerivative · entry 1 Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,702,609 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $8.6895 to $8.7811. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
February 20, 2024 Filed Feb 22, 2024 22:01 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantCommon Stock	22,800	$2.50	$57,000.00	Disclosure SEC source: 0000950170-24-018893 · ownership.xml · nonDerivative · entry 1 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,556 F1 · shares: Represents Restricted Stock Units that vest in four equal quarterly installments beginning on March 15, 2024. The Reporting Person has deferred settlement of the Restricted Stock Units until the earlier to occur of the Reporting Person's termination of service and a change of control. F2 · price: The Restricted Stock Units were issued to the Reporting Person, who elected to take Restricted Stock Units in lieu of $57,000 in cash compensation for services as a board member. Read SEC document
January 05, 2024 Filed Jan 9, 2024 23:06 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantWarrant to purchase common stock (Right to buy) · Derivative	4,824,802	Not disclosed Strike: $11.50	Not disclosed	Disclosure SEC source: 0001104659-24-002655 · tm242400-7_4seq1.xml · derivative · entry 11 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · CMLS Holdings LLC Disclosed balance after: 4,824,802 Underlying: Common Stock · 4,824,802 shares Expires 2026-09-01 F12 · shares: 25% of the shares underlying the option vested on February 19, 2022, with the remaining shares vesting in equally monthly installments started on the 1st day of the following month until fully vested, subject to the Reporting Person's continued service through the applicable vesting date. F13 · price: Pursuant to the Merger Agreement, each warrant to purchase SomaLogic common stock was treated in accordance with its terms on and after the Effective Time and each warrant will convert into the right to receive, upon exercise of such warrant, the number of shares of common stock of the Company equal to multiplying the number of shares of common stock of SomaLogic subject to such warrant by the Exchange Ratio. The securities are held of record by CMLS Holdings II. See footnote 4 for more information. F12 · ownership.nature: 25% of the shares underlying the option vested on February 19, 2022, with the remaining shares vesting in equally monthly installments started on the 1st day of the following month until fully vested, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
January 05, 2024 Filed Jan 9, 2024 23:06 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantStock Option (Right to buy) · Derivative	46,514	Not disclosed Strike: $4.30	Not disclosed	Disclosure SEC source: 0001104659-24-002655 · tm242400-7_4seq1.xml · derivative · entry 10 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,514 Underlying: Common Stock · 46,514 shares Expires 2031-02-18 F9 · price: Pursuant to the Merger Agreement, each option to purchase SomaLogic common stock (a "SomaLogic Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Company equal to the product of (i) the number of shares subject to such SomaLogic Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the SomaLogic Option by the Exchange Ratio, rounded up to the nearest whole cent. Except as noted above, each assumed SomaLogic Option will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such SomaLogic Option immediately prior to the Effective Time. F12 · derivative.exercise_date: 25% of the shares underlying the option vested on February 19, 2022, with the remaining shares vesting in equally monthly installments started on the 1st day of the following month until fully vested, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
January 05, 2024 Filed Jan 9, 2024 23:06 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantStock Option (Right to buy) · Derivative	22,866	Not disclosed Strike: $2.08	Not disclosed	Disclosure SEC source: 0001104659-24-002655 · tm242400-7_4seq1.xml · derivative · entry 9 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,866 Underlying: Common Stock · 22,866 shares Expires 2033-03-16 F9 · price: Pursuant to the Merger Agreement, each option to purchase SomaLogic common stock (a "SomaLogic Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Company equal to the product of (i) the number of shares subject to such SomaLogic Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the SomaLogic Option by the Exchange Ratio, rounded up to the nearest whole cent. Except as noted above, each assumed SomaLogic Option will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such SomaLogic Option immediately prior to the Effective Time. F11 · derivative.exercise_date: 100% of the shares underlying the option vest on March 17, 2024, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
January 05, 2024 Filed Jan 9, 2024 23:06 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantStock Option (Right to buy) · Derivative	22,866	Not disclosed Strike: $8.19	Not disclosed	Disclosure SEC source: 0001104659-24-002655 · tm242400-7_4seq1.xml · derivative · entry 8 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,866 Underlying: Common Stock · 22,866 shares Expires 2032-02-29 F9 · price: Pursuant to the Merger Agreement, each option to purchase SomaLogic common stock (a "SomaLogic Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Company equal to the product of (i) the number of shares subject to such SomaLogic Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the SomaLogic Option by the Exchange Ratio, rounded up to the nearest whole cent. Except as noted above, each assumed SomaLogic Option will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such SomaLogic Option immediately prior to the Effective Time. F10 · derivative.exercise_date: This option is fully vested and currently exercisable. Read SEC document
January 05, 2024 Filed Jan 9, 2024 23:06 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantStock Option (Right to buy) · Derivative	51,842	Not disclosed Strike: $10.68	Not disclosed	Disclosure SEC source: 0001104659-24-002655 · tm242400-7_4seq1.xml · derivative · entry 7 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,842 Underlying: Common Stock · 51,842 shares Expires 2031-10-26 F9 · price: Pursuant to the Merger Agreement, each option to purchase SomaLogic common stock (a "SomaLogic Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Company equal to the product of (i) the number of shares subject to such SomaLogic Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the SomaLogic Option by the Exchange Ratio, rounded up to the nearest whole cent. Except as noted above, each assumed SomaLogic Option will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such SomaLogic Option immediately prior to the Effective Time. F8 · derivative.exercise_date: 25% of the shares underlying the option vested on October 27, 2022, with the remaining shares vesting in equal monthly installments thereafter starting on the 1st of the following month until fully vested, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
January 05, 2024 Filed Jan 9, 2024 23:06 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantCommon Stock	2,744,219	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-002655 · tm242400-7_4seq1.xml · nonDerivative · entry 5 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Casdin Private Growth Equity Fund, L.P. Disclosed balance after: 2,744,219 F6 · shares: Received in exchange for 2,472,270 shares of common stock of SomaLogic pursuant to the Merger. The shares held by Casdin Private Growth Equity Fund, L.P. may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Private Growth Equity Fund, L.P., (ii) Casdin Private Growth Equity GP, LLC, the general partner of Casdin Private Growth Equity Fund, L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Private Growth Equity GP, LLC. F6 · price: Received in exchange for 2,472,270 shares of common stock of SomaLogic pursuant to the Merger. The shares held by Casdin Private Growth Equity Fund, L.P. may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Private Growth Equity Fund, L.P., (ii) Casdin Private Growth Equity GP, LLC, the general partner of Casdin Private Growth Equity Fund, L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Private Growth Equity GP, LLC. F6 · ownership.nature: Received in exchange for 2,472,270 shares of common stock of SomaLogic pursuant to the Merger. The shares held by Casdin Private Growth Equity Fund, L.P. may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Private Growth Equity Fund, L.P., (ii) Casdin Private Growth Equity GP, LLC, the general partner of Casdin Private Growth Equity Fund, L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Private Growth Equity GP, LLC. Read SEC document
January 05, 2024 Filed Jan 9, 2024 23:06 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantCommon Stock	11,246,525	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-002655 · tm242400-7_4seq1.xml · nonDerivative · entry 4 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Casdin Partners Master Fund, L.P. Disclosed balance after: 11,246,525 F5 · shares: Received in exchange for 10,132,055 shares of common stock of SomaLogic pursuant to the Merger. The shares reflected as beneficially owned by Casdin Partners Master Fund, L.P. in the table above are owned directly by Casdin Partners Master Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, L.P., (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. F5 · price: Received in exchange for 10,132,055 shares of common stock of SomaLogic pursuant to the Merger. The shares reflected as beneficially owned by Casdin Partners Master Fund, L.P. in the table above are owned directly by Casdin Partners Master Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, L.P., (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. F5 · ownership.nature: Received in exchange for 10,132,055 shares of common stock of SomaLogic pursuant to the Merger. The shares reflected as beneficially owned by Casdin Partners Master Fund, L.P. in the table above are owned directly by Casdin Partners Master Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, L.P., (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Read SEC document
January 05, 2024 Filed Jan 9, 2024 23:06 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantCommon Stock	7,548,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-002655 · tm242400-7_4seq1.xml · nonDerivative · entry 3 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By CMLS Holdings II LLC Disclosed balance after: 7,548,000 F4 · shares: Received in exchange for 6,800,000 shares of common stock of SomaLogic pursuant to the Merger. The shares are held of record by CMLS Holdings II LLC ("CMLS Holdings II"). The Board of Managers of CMLS Holdings II includes Mr. Casdin, who, as a member of the Board of Managers of CMLS Holdings III, shares voting and investment discretion with respect to the common stock held by CMLS Holdings II. Mr. Casdin may be deemed to have or share beneficial ownership of the securities held by CMLS Holdings II, which inlcude such shares and the warrants referenced in Table II. F4 · price: Received in exchange for 6,800,000 shares of common stock of SomaLogic pursuant to the Merger. The shares are held of record by CMLS Holdings II LLC ("CMLS Holdings II"). The Board of Managers of CMLS Holdings II includes Mr. Casdin, who, as a member of the Board of Managers of CMLS Holdings III, shares voting and investment discretion with respect to the common stock held by CMLS Holdings II. Mr. Casdin may be deemed to have or share beneficial ownership of the securities held by CMLS Holdings II, which inlcude such shares and the warrants referenced in Table II. F4 · ownership.nature: Received in exchange for 6,800,000 shares of common stock of SomaLogic pursuant to the Merger. The shares are held of record by CMLS Holdings II LLC ("CMLS Holdings II"). The Board of Managers of CMLS Holdings II includes Mr. Casdin, who, as a member of the Board of Managers of CMLS Holdings III, shares voting and investment discretion with respect to the common stock held by CMLS Holdings II. Mr. Casdin may be deemed to have or share beneficial ownership of the securities held by CMLS Holdings II, which inlcude such shares and the warrants referenced in Table II. Read SEC document
January 05, 2024 Filed Jan 9, 2024 23:06 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantCommon Stock	3,807	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-002655 · tm242400-7_4seq1.xml · nonDerivative · entry 2 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,756 F2 · shares: Represents Restricted Stock Units ("RSUs") that vest in four equal annual installments beginning March 17, 2024, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. F3 · price: Pursuant to the Merger Agreement, each RSU convertible into shares of SomaLogic common stock (a "SomaLogic RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of common stock of the Company equal to the to the product of (i) the number of shares subject to such SomaLogic RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Company common stock rounded to the next nearest whole share. Except as noted above, each assumed SomaLogic RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such SomaLogic RSU immediately prior to the Effective Time. Read SEC document
January 05, 2024 Filed Jan 9, 2024 23:06 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantCommon Stock	3,807	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-002655 · tm242400-7_4seq1.xml · nonDerivative · entry 1 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,949 F1 · shares: Received in exchange for 3,430 shares of common stock of SomaLogic, Inc. ("SomaLogic") pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated October 4, 2023, by and among Standard BioTools Inc. (the "Company"), Martis Merger Sub, Inc. and SomaLogic (the "Merger"). Per the terms of the Merger, each share of SomaLogic common stock was converted into the right to receive 1.11 shares of the Company's common stock (the "Exchange Ratio") at the effective time of the Merger (the "Effective Time"). F1 · price: Received in exchange for 3,430 shares of common stock of SomaLogic, Inc. ("SomaLogic") pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated October 4, 2023, by and among Standard BioTools Inc. (the "Company"), Martis Merger Sub, Inc. and SomaLogic (the "Merger"). Per the terms of the Merger, each share of SomaLogic common stock was converted into the right to receive 1.11 shares of the Company's common stock (the "Exchange Ratio") at the effective time of the Merger (the "Effective Time"). Read SEC document
January 05, 2024 Filed Jan 10, 2024 02:46 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerWarrant to purchase common stock (Right to buy) · Derivative	4,346,669	Not disclosed Strike: $11.50	Not disclosed	Disclosure SEC source: 0001209191-24-001324 · doc4.xml · derivative · entry 10 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By CMLS Holdings II LLC Disclosed balance after: 0 Underlying: Common Stock · 4,346,669 shares Expires 2026-09-01 F15 · price: Pursuant to the Merger Agreement, each warrant to purchase Company Common Stock was treated in accordance with its terms on and after the Effective Time and each warrant will convert into the right to receive, upon exercise of such warrant, the number of shares of Parent Common Stock equal to multiplying the number of shares of Company Common Stock subject to such warrant by the Exchange Ratio. F14 · derivative.exercise_date: Each warrant is exercisable to purchase one share of Company Common Stock at a price of $11.50 per share, subject to adjustment, as described in the Issuer's Annual Report on Form 10-K, for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission on March 28, 2023. F3 · ownership.nature: The shares are held of record by CMLS Holdings II LLC ("CMLS Holdings II"). The Board of Managers of CMLS Holdings II includes Mr. Casdin, who, as a member of the Board of Managers of CMLS Holdings II, shares voting and investment discretion with respect to the common stock held by CMLS Holdings II. Mr. Casdin may be deemed to have or share beneficial ownership of the securities held by CMLS Holdings II, which include such shares and the warrants referenced in Table II. Read SEC document
January 05, 2024 Filed Jan 10, 2024 02:46 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerRestricted Stock Unit · Derivative	3,430	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-24-001324 · doc4.xml · derivative · entry 9 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,430 shares Expires not disclosed F11 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F13 · price: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F12 · derivative.exercise_date: The RSUs shall be 100% vested on March 17, 2024, subject to the continued service of the Reporting Person on such vesting date. F12 · derivative.expiration_date: The RSUs shall be 100% vested on March 17, 2024, subject to the continued service of the Reporting Person on such vesting date. Read SEC document
January 05, 2024 Filed Jan 10, 2024 02:46 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerStock Option (Right to buy) · Derivative	20,600	Not disclosed Strike: $2.30	Not disclosed	Disclosure SEC source: 0001209191-24-001324 · doc4.xml · derivative · entry 8 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,600 shares Expires 2033-03-16 F7 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F10 · derivative.exercise_date: The option shall be 100% vested on March 17, 2024, subject to the continued service of the Reporting Person on such vesting date. Read SEC document
January 05, 2024 Filed Jan 10, 2024 02:46 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerStock Option (Right to buy) · Derivative	20,600	Not disclosed Strike: $9.08	Not disclosed	Disclosure SEC source: 0001209191-24-001324 · doc4.xml · derivative · entry 7 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,600 shares Expires 2032-02-29 F7 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F9 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document
January 05, 2024 Filed Jan 10, 2024 02:46 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerStock Option (Right to buy) · Derivative	46,705	Not disclosed Strike: $11.85	Not disclosed	Disclosure SEC source: 0001209191-24-001324 · doc4.xml · derivative · entry 6 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,705 shares Expires 2031-10-26 F7 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F8 · derivative.exercise_date: The option vested as to 1/4th of the total grant on October 27, 2022, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document
January 05, 2024 Filed Jan 10, 2024 02:46 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerStock Option (Right to buy) · Derivative	41,905	Not disclosed Strike: $4.77	Not disclosed	Disclosure SEC source: 0001209191-24-001324 · doc4.xml · derivative · entry 5 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,905 shares Expires 2031-02-18 F7 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F6 · derivative.exercise_date: The option vested as to 1/4th of the total grant on February 19, 2022, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document
January 05, 2024 Filed Jan 10, 2024 02:46 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerCommon Stock	2,472,270	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-24-001324 · doc4.xml · nonDerivative · entry 4 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Casdin Private Growth Equity Fund, L.P. Disclosed balance after: 0 F1 · price: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2 · price: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock. F5 · ownership.nature: The shares held by Casdin Private Growth Equity Fund, L.P. may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Private Growth Equity Fund, L.P., (ii) Casdin Private Growth Equity GP, LLC, the general partner of Casdin Private Growth Equity Fund, L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Private Growth Equity GP, LLC. Read SEC document
January 05, 2024 Filed Jan 10, 2024 02:46 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerCommon Stock	10,132,005	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-24-001324 · doc4.xml · nonDerivative · entry 3 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Casdin Master Fund, L.P. Disclosed balance after: 0 F1 · price: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2 · price: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, LP (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Read SEC document
January 05, 2024 Filed Jan 10, 2024 02:46 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerCommon Stock	6,800,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-24-001324 · doc4.xml · nonDerivative · entry 2 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By CMLS Holdings II LLC Disclosed balance after: 0 F1 · price: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2 · price: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock. F3 · ownership.nature: The shares are held of record by CMLS Holdings II LLC ("CMLS Holdings II"). The Board of Managers of CMLS Holdings II includes Mr. Casdin, who, as a member of the Board of Managers of CMLS Holdings II, shares voting and investment discretion with respect to the common stock held by CMLS Holdings II. Mr. Casdin may be deemed to have or share beneficial ownership of the securities held by CMLS Holdings II, which include such shares and the warrants referenced in Table II. Read SEC document
January 05, 2024 Filed Jan 10, 2024 02:46 UTC	SomaLogic, Inc. SLGC · Entity 95310	Disposition to issuerCommon Stock	3,430	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-24-001324 · doc4.xml · nonDerivative · entry 1 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2 · price: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock. Read SEC document
November 09, 2023 Filed Nov 14, 2023 08:33 UTC	EQRx, Inc. EQRX · Entity 108311	OtherStock Option (Right to Buy) · Derivative	101,010	$0.00 Strike: $4.95	$0.00	Disclosure SEC source: 0000919574-23-006265 · ownership.xml · derivative · entry 9 Casdin Eli · CIK 0001534264 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 101,010 shares Expires 2032-09-30 F6 · derivative.exercise_date: The shares underlying this option vested and became exercisable in full on September 30, 2023, the one-year anniversary of the grant date, subject to the Reporting Person's continuous service on such vesting date, and subject to full acceleration upon the consummation of a Sale Event (as defined in the Issuer's 2021 Stock Option and Incentive Plan). Read SEC document
November 09, 2023 Filed Nov 14, 2023 08:33 UTC	EQRx, Inc. EQRX · Entity 108311	OtherEarn-out Shares · Derivative	755,766	Not disclosed	Not disclosed	Disclosure SEC source: 0000919574-23-006265 · ownership.xml · derivative · entry 8 Casdin Eli · CIK 0001534264 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 755,766 shares Expires 2024-12-17 F5 · derivative.exercise_price: The Reporting Person received the right to acquire an aggregate of 4,729,839 shares of the Issuer's Common Stock (the "Earn-out Shares") (i) 3,310,887 of which were to be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $12.50; and (ii) 1,418,952 would have been released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 would have been forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire was subject to adjustment. F5 · price: The Reporting Person received the right to acquire an aggregate of 4,729,839 shares of the Issuer's Common Stock (the "Earn-out Shares") (i) 3,310,887 of which were to be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $12.50; and (ii) 1,418,952 would have been released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 would have been forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire was subject to adjustment. F5 · derivative.exercise_date: The Reporting Person received the right to acquire an aggregate of 4,729,839 shares of the Issuer's Common Stock (the "Earn-out Shares") (i) 3,310,887 of which were to be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $12.50; and (ii) 1,418,952 would have been released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 would have been forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire was subject to adjustment. F4 · ownership.nature: The securities were owned directly by Casdin Private Growth Equity Fund, L.P. (the "Private Fund") and were deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to the Private Fund, (ii) Casdin Private Growth Equity Fund GP, LLC (the "Private GP"), the general partner of the Private Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Private GP Read SEC document
November 09, 2023 Filed Nov 14, 2023 08:33 UTC	EQRx, Inc. EQRX · Entity 108311	OtherEarn-out Shares · Derivative	526,674	Not disclosed	Not disclosed	Disclosure SEC source: 0000919574-23-006265 · ownership.xml · derivative · entry 7 Casdin Eli · CIK 0001534264 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 526,674 shares Expires 2024-12-17 F5 · derivative.exercise_price: The Reporting Person received the right to acquire an aggregate of 4,729,839 shares of the Issuer's Common Stock (the "Earn-out Shares") (i) 3,310,887 of which were to be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $12.50; and (ii) 1,418,952 would have been released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 would have been forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire was subject to adjustment. F5 · price: The Reporting Person received the right to acquire an aggregate of 4,729,839 shares of the Issuer's Common Stock (the "Earn-out Shares") (i) 3,310,887 of which were to be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $12.50; and (ii) 1,418,952 would have been released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 would have been forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire was subject to adjustment. F5 · derivative.exercise_date: The Reporting Person received the right to acquire an aggregate of 4,729,839 shares of the Issuer's Common Stock (the "Earn-out Shares") (i) 3,310,887 of which were to be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $12.50; and (ii) 1,418,952 would have been released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 would have been forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire was subject to adjustment. F3 · ownership.nature: The securities were owned directly by Casdin Venture Opportunities Fund, L.P. (the "Venture Fund") and were deemed to be indirectly bencially owned by (i) Casdin Capital, the investment adviser to the Venture Fund, (ii) Casdin Venture Opportunities Fund GP, LLC (the "Venture GP"), the general partner of the Venture Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Venture GP. Read SEC document
November 09, 2023 Filed Nov 14, 2023 08:33 UTC	EQRx, Inc. EQRX · Entity 108311	OtherEarn-out Shares · Derivative	3,472,300	Not disclosed	Not disclosed	Disclosure SEC source: 0000919574-23-006265 · ownership.xml · derivative · entry 6 Casdin Eli · CIK 0001534264 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 3,472,300 shares Expires 2024-12-17 F5 · derivative.exercise_price: The Reporting Person received the right to acquire an aggregate of 4,729,839 shares of the Issuer's Common Stock (the "Earn-out Shares") (i) 3,310,887 of which were to be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $12.50; and (ii) 1,418,952 would have been released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 would have been forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire was subject to adjustment. F5 · price: The Reporting Person received the right to acquire an aggregate of 4,729,839 shares of the Issuer's Common Stock (the "Earn-out Shares") (i) 3,310,887 of which were to be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $12.50; and (ii) 1,418,952 would have been released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 would have been forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire was subject to adjustment. F5 · derivative.exercise_date: The Reporting Person received the right to acquire an aggregate of 4,729,839 shares of the Issuer's Common Stock (the "Earn-out Shares") (i) 3,310,887 of which were to be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $12.50; and (ii) 1,418,952 would have been released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 was at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 would have been forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire was subject to adjustment. F2 · ownership.nature: The securities were owned directly by the Casdin Partners Master Fund, L.P. (the "Master Fund") and were deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to the Master Fund, (ii) Casdin GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Mr. Casdin disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.) Read SEC document
November 09, 2023 Filed Nov 14, 2023 08:33 UTC	EQRx, Inc. EQRX · Entity 108311	OtherWarrants to purchase Class A Common Stock (right to buy) · Derivative	8,110,001	$0.00 Strike: $11.50	$0.00	Disclosure SEC source: 0000919574-23-006265 · ownership.xml · derivative · entry 5 Casdin Eli · CIK 0001534264 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 8,110,001 shares Expires 2026-12-17 F1 · ownership.nature: The securities were held directly by CMLS Holdings III LLC ("CMLS Holdings III"). Mr. Casdin is a member of the Board of Managers of CMLS Holdings III and as a result shares voting and investment discretion with respect to the securities held by CMLS Holdings III. Mr. Casdin disclaims beneficial ownership of these shares except to the extent of his respective pecuniary interest therein. Read SEC document
November 09, 2023 Filed Nov 14, 2023 08:33 UTC	EQRx, Inc. EQRX · Entity 108311	OtherCommon Stock	5,488,164	$0.00	$0.00	Disclosure SEC source: 0000919574-23-006265 · ownership.xml · nonDerivative · entry 4 Casdin Eli · CIK 0001534264 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F4 · ownership.nature: The securities were owned directly by Casdin Private Growth Equity Fund, L.P. (the "Private Fund") and were deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to the Private Fund, (ii) Casdin Private Growth Equity Fund GP, LLC (the "Private GP"), the general partner of the Private Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Private GP Read SEC document
November 09, 2023 Filed Nov 14, 2023 08:33 UTC	EQRx, Inc. EQRX · Entity 108311	OtherCommon Stock	3,824,572	$0.00	$0.00	Disclosure SEC source: 0000919574-23-006265 · ownership.xml · nonDerivative · entry 3 Casdin Eli · CIK 0001534264 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F3 · ownership.nature: The securities were owned directly by Casdin Venture Opportunities Fund, L.P. (the "Venture Fund") and were deemed to be indirectly bencially owned by (i) Casdin Capital, the investment adviser to the Venture Fund, (ii) Casdin Venture Opportunities Fund GP, LLC (the "Venture GP"), the general partner of the Venture Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Venture GP. Read SEC document
November 09, 2023 Filed Nov 14, 2023 08:33 UTC	EQRx, Inc. EQRX · Entity 108311	OtherCommon Stock	30,214,934	$0.00	$0.00	Disclosure SEC source: 0000919574-23-006265 · ownership.xml · nonDerivative · entry 2 Casdin Eli · CIK 0001534264 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F2 · ownership.nature: The securities were owned directly by the Casdin Partners Master Fund, L.P. (the "Master Fund") and were deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to the Master Fund, (ii) Casdin GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Mr. Casdin disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.) Read SEC document
November 09, 2023 Filed Nov 14, 2023 08:33 UTC	EQRx, Inc. EQRX · Entity 108311	OtherCommon Stock	8,659,372	$0.00	$0.00	Disclosure SEC source: 0000919574-23-006265 · ownership.xml · nonDerivative · entry 1 Casdin Eli · CIK 0001534264 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · ownership.nature: The securities were held directly by CMLS Holdings III LLC ("CMLS Holdings III"). Mr. Casdin is a member of the Board of Managers of CMLS Holdings III and as a result shares voting and investment discretion with respect to the securities held by CMLS Holdings III. Mr. Casdin disclaims beneficial ownership of these shares except to the extent of his respective pecuniary interest therein. Read SEC document
October 19, 2023 Filed Oct 23, 2023 21:42 UTC	BIOLIFE SOLUTIONS INC BLFS · Entity 4614	PurchaseCommon Stock, par value $.001 per share	927,165	$11.19	$10,374,976.35	Disclosure SEC source: 0000919574-23-005783 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · 10% owner Casdin Eli · CIK 0001534264 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,557,165 F1 · ownership.direct: The securities are owned directly by the Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.